Top 5 Drug Type | Count |
---|---|
Proteolysis-targeting chimeras (PROTAC) | 17 |
Small molecule drug | 16 |
Fusion protein | 4 |
Chemical drugs | 2 |
Synthetic peptide | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism AR antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SARS-CoV-2 Mpro inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2025 |
Sponsor / Collaborator |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Peptide Lv ( VEGFR2 ) | Atherosclerosis More | Preclinical |
Indole-3-acetate(Texas A&M University) ( AMPK ) | Metabolic dysfunction-associated steatotic liver disease More | Preclinical |
RTI-79 | Diffuse Large B-Cell Lymphoma More | Preclinical |
pal-pom ( CDK4 x CDK6 ) | Neoplasms More | Preclinical |
MPD10 ( SARS-CoV-2 Mpro ) | Coronavirus Infections More | Preclinical |